Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Obseva SA    OBSV   CH0346177709

OBSEVA SA (OBSV)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
12.18(c) 11.87(c) 12.59(c) 12.48(c) 14.13(c) Last
10 418 5 603 11 471 2 718 70 477 Volume
-0.08% -2.55% +6.07% -0.87% +13.22% Change
More quotes
Financials ($)
Sales 2017 0,01 M
EBIT 2017 -68,5 M
Net income 2017 -67,5 M
Finance 2017 126 M
Yield 2017 -
Sales 2018 0,01 M
EBIT 2018 -79,2 M
Net income 2018 -78,9 M
Finance 2018 98,6 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 48 598x
EV / Sales2018 49 547x
Capitalization 525 M
More Financials
Company
ObsEva SA engages in the development of therapeutic treatments for woman's reproductive health and pregnancy.It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth.The company was founded by Ernest Loumaye and André Chollet in November 2012 and is... 
More about the company
Surperformance© ratings of Obseva SA
Trading Rating : Investor Rating :
More Ratings
Latest news on OBSEVA SA
2017ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm La..
GL
2017ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with..
GL
2017ObsEva SA to Hold First Quarter 2017 Financial Results and Business Update Ca..
GL
2017OBSEVA : Starts Phase 3 Clinical Program for Nolasiban in ART
PU
More news
Sector news : Bio Therapeutic Drugs
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
04:17aObseva SA $OBSV Receives Average Rating of “Buy” from Analysts  
02/09Obseva $OBSV Stock Rating Reaffirmed by HC Wainwright
1
02/07ObsEva SA to present at the LEERINK Partners 7th Annual Global Healthcare Con.. 
02/07ObsEva SA to present at the LEERINK Partners 7th Annual Global Healthcare Con.. 
02/05H.C. Wainwright Sticks to Their Buy Rating for ObsEva SA $OBSV  
More tweets
Qtime:43
News from SeekingAlpha
02/05OBSEVA : Obstetrics And Women's Health 
01/23After Hours Gainers / Losers (1/23/2018) 
2017YOUR DAILY PHARMA SCOOP : Aclaris Gets Approval, Egalet Surges, Alnylam Gains As.. 
2017YOUR DAILY PHARMA SCOOP : Acadia Valuation, Galectin Plunges, Revance Positive R.. 
2017ObsEva launches mid-stage study of OBE022 in pregnant women with preterm labo.. 
Chart OBSEVA SA
Duration : Period :
Obseva SA Technical Analysis Chart | OBSV | CH0346177709 | 4-Traders
Technical analysis trends OBSEVA SA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 20,2 $
Spread / Average Target 43%
EPS Revisions
Managers
NameTitle
Ernest Loumaye Chief Executive Officer & Director
Frank A. G. M. Verwiel Chairman
Timothy M. Adams Chief Financial Officer
Jean-Pierre Gotteland Chief Scientific Officer
Elke Bestel Chief Medical Officer & Head-Pharmacovigilance
Sector and Competitors
1st jan.Capitalization (M$)
OBSEVA SA29.00%467
GILEAD SCIENCES14.21%106 851
VERTEX PHARMACEUTICALS4.94%39 772
REGENERON PHARMACEUTICALS-12.04%35 529
BIOVERATIV INC91.99%11 201
GENMAB4.28%11 055